METHOD FOR PREDICTION OF DEGREE OF FULL REGRESSION PROBABILITY DURING NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH LUMINAL MOLECULAR-GENETIC SUBTYPE OF BREAST CANCER Russian patent published in 2017 - IPC G01N33/48 

FIELD: medicine.

SUBSTANCE: histological study of primary neoplasm tissue preparations is performed prior to neoadjuvant chemotherapy. In the preparations, the infiltrative component is evaluated, where the presence of trabecular, tubular, alveolar, solid structures and discrete groups of tumour cells is determined. The stromal component is then evaluated. Presence or absence of discrete groups of tumour cells is determined in the infiltrative component of the tumour. In the tumour stroma, the severity of inflammatory infiltration, the degree of malignancy are estimated. An immunohistochemical study is performed to evaluate the expression of bcl-2, P-glycoprotein in inflammatory infiltrate cells, membrane expression of MRP2 in tumour cells. Malignancy degree of X ₁ at the first degree is estimated as 1 point, at the second - as 2 points, at the third - as 3 points. The presence of discrete cell groups X₂ in the infiltrative component; the absence is estimated as 1 point, the presence - as 2 points. Presence of bcl-2-positive cells X₃ in the inflammatory infiltrate is estimated as 2 points, absence - as 1 point. Positive expression of P-glycoprotein in inflammatory infiltrate cells X₄ is estimated as 2 points, absence - as 1 point. The presence of membrane expression of MRP2 in tumour cells X₅ is estimated as 2 points, absence - as 1 point. Further, the value of the regression equation Y is calculated from the formula: Y=5-3.0X₁-18.5X₂-25.5X₃+75.6X₄-19.8X₅, further, the value of the probability of complete tumour regression P is determined by the formula: P=e^Y/(1+e^Y), and at P≥0.5, a high, and at P<0.5, a low probability of complete regression after neoadjuvant chemotherapy is predicted.

EFFECT: increased accuracy of forecasting.

2 ex